Furthermore O
, O
we O
observed O
no O
correlation O
between O
the O
somatic O
mutation O
rate O
and O
tissue O
proliferation O
capacity O
. O

The O
somatic O
mutation O
rates O
in O
different O
tissues O
were O
also O
not O
correlated O
to O
the O
relative O
inter O
- O
tissue O
difference O
in O
transcriptional O
levels O
of O
the O
three O
genes O
( O
DMAHP O
, O
DMPK O
and O
59 O
) O
surrounding O
the O
repeat O
. O
. O

A O
novel O
missense O
mutation O
in O
patients O
from O
a O
retinoblastoma B
pedigree O
showing O
only O
mild O
expression O
of O
the O
tumor B
phenotype O
. O

We O
have O
used O
single O
strand O
conformation O
polymorphism O
analysis O
to O
study O
the O
27 O
exons O
of O
the O
RB1 O
gene O
in O
individuals O
from O
a O
family O
showing O
mild O
expression O
of O
the O
retinoblastoma B
phenotype O
. O

In O
this O
family O
affected O
individuals O
developed O
unilateral B
tumors I
and O
, O
as O
a O
result O
of O
linkage O
analysis O
, O
unaffected O
mutation O
carriers O
were O
also O
identified O
within O
the O
pedigree O
. O

A O
single O
band O
shift O
using O
SSCP O
was O
identified O
in O
exon O
21 O
which O
resulted O
in O
a O
missense O
mutation O
converting O
a O
cys O
- O
- O
> O
arg O
at O
nucleotide O
position O
28 O
in O
the O
exon O
. O

The O
mutation O
destroyed O
an O
NdeI O
restriction O
enzyme O
site O
. O

Analysis O
of O
all O
family O
members O
demonstrated O
that O
the O
missense O
mutation O
co O
- O
segregated O
with O
patients O
with O
tumors B
or O
who O
, O
as O
a O
result O
of O
linkage O
analysis O
had O
been O
predicted O
to O
carry O
the O
predisposing O
mutation O
. O

These O
observations O
point O
to O
another O
region O
of O
the O
RB1 O
gene O
where O
mutations O
only O
modify O
the O
function O
of O
the O
gene O
and O
raise O
important O
questions O
for O
genetic O
counseling O
in O
families O
with O
these O
distinctive O
phenotypes O
. O
. O

Maternal B
disomy I
and O
Prader B
- I
Willi I
syndrome I
consistent O
with O
gamete O
complementation O
in O
a O
case O
of O
familial O
translocation O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
. O

Maternal B
uniparental I
disomy I
( I
UPD I
) I
for I
chromosome I
15 I
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

We O
report O
on O
an O
unusual O
case O
of O
maternal B
disomy I
15 I
in O
PWS B
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
with O
simultaneous O
maternal O
meiotic O
nondisjunction O
for O
chromosome O
15 O
. O

The O
patient O
( O
J O
. O
B O
. O
) O
, O
a O
17 O
- O
year O
- O
old O
white O
male O
with O
PWS B
, O
was O
found O
to O
have O
47 O
chromosomes O
with O
a O
supernumerary O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
, O
and O
distal O
chromosome O
arm O
3p O
. O

The O
t O
( O
3 O
; O
15 O
) O
was O
present O
in O
the O
balanced O
state O
in O
the O
patients O
father O
and O
a O
sister O
. O

Fluorescent O
in O
situ O
hybridization O
analysis O
demonstrated O
that O
the O
PWS B
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
deletion O
of O
the O
PWS B
region O
on O
the O
normal O
pair O
of O
15s O
present O
in O
J O
. O

B O
. O

Methylation O
analysis O
at O
exon O
alpha O
of O
the O
small O
nuclear O
ribonucleoprotein O
- O
associated O
polypeptide O
N O
( O
SNRPN O
) O
gene O
showed O
a O
pattern O
characteristic O
of O
only O
the O
maternal O
chromosome O
15 O
in O
J O
. O

B O
. O

Maternal B
disomy I
was O
confirmed O
by O
polymerase O
chain O
reaction O
analysis O
of O
microsatellite O
repeats O
at O
the O
gamma O
- O
aminobutyric O
acid O
receptor O
beta3 O
subunit O
( O
GABRB3 O
) O
locus O
. O

A O
niece O
( O
B O
. O
B O
. O
) O
with O
45 O
chromosomes O
and O
the O
derivative O
3 O
but O
without O
the O
der O
( O
15 O
) O
demonstrated O
a O
phenotype O
consistent O
with O
that O
reported O
for O
haploinsufficiency O
of O
distal O
3 O
p O
. O

Uniparental B
disomy I
associated O
with O
unbalanced O
segregation O
of O
non O
- O
Robertsonian O
translocations O
has O
been O
reported O
previously O
but O
has O
not O
, O
to O
our O
knowledge O
, O
been O
observed O
in O
a O
case O
of O
PWS B
. O

Furthermore O
, O
our O
findings O
are O
best O
interpreted O
as O
true O
gamete O
complementation O
resulting O
in O
maternal B
UPD I
15 I
and O
PWS B

Schwartz B
- I
Jampel I
syndrome I
type I
2 I
and O
Stuve B
- I
Wiedemann I
syndrome I
: O
a O
case O
for O
" O
lumping O
" O
. O

Recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
) O
of O
myotonia B
and O
skeletal B
dysplasia I
, O
which O
we O
called O
SJS B
type I
2 I
. O

This O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
Stuve B
- I
Wiedemann I
syndrome I
( O
SWS B
) O
, O
which O
comprises O
campomelia B
at O
birth O
with O
skeletal B
dysplasia I
, O
contractures B
, O
and O
early B
death I
. O

To O
test O
for O
possible O
nosologic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
SJS B
type I
2 I
at O
age O
10 O
years O
and O
another O
with O
SWS B
at O
age O
7 O
years O
. O

Patients O
reported O
as O
having O
either O
neonatal O
SJS B
or O
SWS B
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B
disorder I
( O
with O
congenital B
joint I
contractures I
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B
- I
metaphyseal I
skeletal I
dysplasia I
. O

The O
similarity O
of O
the O
clinical O
and O
radiographic O
findings O
is O
so O
extensive O
that O
these O
disorders O
appear O
to O
be O
a O
single O
entity O
. O

The O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B
dysplasia I
in O
the O
two O
patients O
( O
one O
with O
SJS B
type I
2 I
, O
one O
with O
SWS B
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

The O
hypothesis O
that O
SWS B
and O
SJS B
type I
2 I
are O
the O
same O
disorder O
should O
be O
testable O
by O
molecular O
methods O
. O
. O

A O
mouse O
model O
of O
severe O
von B
Willebrand I
disease I
: O
defects O
in O
hemostasis O
and O
thrombosis B
. O

von B
Willebrand I
factor I
( I
vWf I
) I
deficiency I
causes O
severe O
von B
Willebrand I
disease I
in O
humans O
. O

We O
generated O
a O
mouse O
model O
for O
this O
disease O
by O
using O
gene O
targeting O
. O

vWf B
- I
deficient I
mice O
appeared O
normal O
at O
birth O
; O
they O
were O
viable O
and O
fertile O
. O

Neither O
vWf O
nor O
vWf O
propolypeptide O
( O
von B
Willebrand I
antigen O
II O
) O
were O
detectable O
in O
plasma O
, O
platelets O
, O
or O
endothelial O
cells O
of O
the O
homozygous O
mutant O
mice O
. O

The O
mutant O
mice O
exhibited O
defects O
in O
hemostasis O
with O
a O
highly O
prolonged O
bleeding O
time O
and O
spontaneous O
bleeding O
events O
in O
approximately O
10 O
% O
of O
neonates O
. O

As O
in O
the O
human O
disease O
, O
the O
factor O
VIII O
level O
in O
these O
mice O
was O
reduced O
strongly O
as O
a O
result O
of O
the O
lack O
of O
protection O
provided O
by O
vWf O
. O

Defective O
thrombosis B
in O
mutant O
mice O
was O
also O
evident O
in O
an O
in O
vivo O
model O
of O
vascular B
injury I
. O

In O
this O
model O
, O
the O
exteriorized O
mesentery O
was O
superfused O
with O
ferric O
chloride O
and O
the O
accumulation O
of O
fluorescently O
labeled O
platelets O
was O
observed O
by O
intravital O
microscopy O
. O

We O
conclude O
that O
these O
mice O
very O
closely O
mimic O
severe O
human O
von B
Willebrand I
disease I
and O
will O
be O
very O
useful O
for O
investigating O
the O
role O
of O
vWf O
in O
normal O
physiology O
and O
in O
disease O
models O
. O
. O

Oral O
contraceptives O
and O
the O
risk O
of O
hereditary B
ovarian I
cancer I
. O

Hereditary B
Ovarian I
Cancer I
Clinical O
Study O
Group O
. O

BACKGROUND O
Women O
with O
mutations O
in O
either O
the O
BRCA1 O
or O
the O
BRCA2 O
gene O
have O
a O
high O
lifetime O
risk O
of O
ovarian B
cancer I
. O

Oral O
contraceptives O
protect O
against O
ovarian B
cancer I
in O
general O
, O
but O
it O
is O
not O
known O
whether O
they O
also O
protect O
against O
hereditary B
forms I
of I
ovarian I
cancer I
. O

METHODS O
We O
enrolled O
207 O
women O
with O
hereditary B
ovarian I
cancer I
and O
161 O
of O
their O
sisters O
as O
controls O
in O
a O
case O
- O
control O
study O
. O

All O
the O
patients O
carried O
a O
pathogenic O
mutation O
in O
either O
BRCA1 O
( O
179 O
women O
) O
or O
BRCA2 O
( O
28 O
women O
) O
. O

The O
control O
women O
were O
enrolled O
regardless O
of O
whether O
or O
not O
they O
had O
either O
mutation O
. O

Lifetime O
histories O
of O
oral O
- O
contraceptive O
use O
were O
obtained O
by O
interview O
or O
by O
written O
questionnaire O
and O
were O
compared O
between O
patients O
and O
control O
women O
, O
after O
adjustment O
for O
year O
of O
birth O
and O
parity O
. O

RESULTS O
The O
adjusted O
odds O
ratio O
for O
ovarian B
cancer I
associated O
with O
any O
past O
use O
of O
oral O
contraceptives O
was O
0 O
. O

5 O
( O
95 O
percent O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
8 O
) O
. O

The O
risk O
decreased O
with O
increasing O
duration O
of O
use O
( O
P O
for O
trend O
, O
< O
0 O
. O
001 O
) O
; O
use O
for O
six O
or O
more O
years O
was O
associated O
with O
a O
60 O
percent O
reduction O
in O
risk O
. O

Oral O
- O
contraceptive O
use O
protected O
against O
ovarian B
cancer I
both O
for O
carriers O
of O
the O
BRCA1 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
5 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
9 O
) O
and O
for O
carriers O
of O
the O
BRCA2 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
4 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
2 O
to O
1 O
. O
1 O
) O
. O

CONCLUSIONS O
Oral O
- O
contraceptive O
use O
may O
reduce O
the O
risk O
of O
ovarian B
cancer I
in O
women O
with O
pathogenic O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O
gene O

A O
Japanese O
family O
with O
adrenoleukodystrophy B
with O
a O
codon O
291 O
deletion O
: O
a O
clinical O
, O
biochemical O
, O
pathological O
, O
and O
genetic O
report O
. O

We O
report O
a O
Japanese O
family O
with O
adrenoleukodystrophy B
( O
ALD B
) O
with O
a O
three O
base O
pair O
deletion O
( O
delGAG O
291 O
) O
in O
the O
ALD B
gene O
. O

A O
variety O
of O
phenotypes O
were O
observed O
within O
this O
family O
. O

While O
the O
proband O
( O
patient O
1 O
) O
was O
classified O
as O
having O
a O
rare O
intermediate O
type O
of O
adult O
cerebral O
and O
cerebello O
- O
brain O
stem O
forms O
, O
his O
younger O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
childhood O
ALD B
type O
. O

Another O
nephew O
( O
patient O
4 O
) O
of O
patient O
1 O
was O
classified O
as O
having O
an O
adolescent O
form O
. O

The O
tau O
level O
in O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
in O
patient O
1 O
was O
as O
high O
as O
that O
of O
patients O
with O
Alzheimers B
disease I
( O
AD B
) O
. O

His O
brain O
magnetic O
resonance O
image O
( O
MRI O
) O
showed O
abnormalities B
in I
the I
bilateral I
cerebellar I
hemispheres I
and O
brain O
stem O
, O
but O
not O
in O
the O
cerebral O
white O
matter O
, O
where O
marked O
reductions O
of O
the O
cerebral O
blood O
flow O
and O
oxygen O
metabolism O
were O
clearly O
demonstrated O
by O
positron O
emission O
tomography O
( O
PET O
) O
. O

In O
patients O
2 O
and O
3 O
, O
the O
autopsy O
findings O
showed O
massive O
demyelination B
of I
the I
cerebral I
white I
matter I
with O
sparing O
of O
the O
U O
- O
fibers O
, O
compatible O
with O
the O
findings O
of O
childhood O
ALD B
. O

Oleic O
and O
erucic O
acids O
( O
Lorenzos O
Oil O
) O
were O
administered O
to O
patients O
1 O
and O
4 O
, O
but O
sufficient O
effectiveness O
was O
not O
obtained O
. O

The O
findings O
in O
this O
family O
suggest O
that O
delGAG291 O
is O
part O
of O
the O
cause O
of O
Japanese O
ALD B
with O
phenotypic O
variations O
. O

Moreover O
, O
although O
the O
scale O
of O
the O
study O
is O
limited O
, O
there O
is O
a O
possibility O
that O
PET O
can O
detect O
an O
insidious B
lesion I
which O
is O
undetectable O
by O
computed O
tomogram O
( O
CT O
) O
or O
MRI O
analysis O
, O
and O
that O
the O
higher O
level O
of O
tau O
reflects O
the O
process O
of O
neuronal B
degeneration I
in O
ALD B
. O

Lorenzos O
Oil O
should O
be O
given O
in O
the O
early O
stage O
. O
. O

Nonsense O
mutation O
in O
exon O
4 O
of O
human O
complement O
C9 O
gene O
is O
the O
major O
cause O
of O
Japanese O
complement B
C9 I
deficiency I
. O

Deficiency B
of I
the I
ninth I
component I
of I
human I
complement I
( O
C9 O
) O
is O
the O
most O
common O
complement B
deficiency I
in O
Japan O
but O
is O
rare O
in O
other O
countries O
. O

We O
studied O
the O
molecular O
basis O
of O
C9 B
deficiency I
in O
four O
Japanese O
C9 B
- I
deficient I
patients O
who O
had O
suffered O
from O
meningococcal B
meningitis I
. O

Direct O
sequencing O
of O
amplified O
C9 O
cDNA O
and O
DNA O
revealed O
a O
nonsense O
substitution O
( O
CGA O
- O
- O
> O
TGA O
) O
at O
codon O
95 O
in O
exon O
4 O
in O
the O
four O
C9 B
- I
deficient I
individuals O
. O

An O
allele O
- O
specific O
polymerase O
chain O
reaction O
system O
designed O
to O
detect O
exclusively O
only O
one O
of O
the O
normal O
and O
mutant O
alleles O
indicated O
that O
all O
the O
four O
patients O
were O
homozygous O
for O
the O
mutation O
in O
exon O
4 O
and O
that O
the O
parents O
of O
patient O
2 O
were O
heterozygous O
. O

The O
common O
mutation O
at O
codon O
95 O
in O
exon O
4 O
might O
be O
responsible O
for O
most O
Japanese O
C9 B
deficiency I
. O
. O

BRCA1 O
required O
for O
transcription O
- O
coupled O
repair O
of O
oxidative O
DNA O
damage O
. O

The O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
encodes O
a O
zinc O
finger O
protein O
of O
unknown O
function O
. O

Association O
of O
the O
BRCA1 O
protein O
with O
the O
DNA O
repair O
protein O
Rad51 O
and O
changes O
in O
the O
phosphorylation O
and O
cellular O
localization O
of O
the O
protein O
after O
exposure O
to O
DNA O
- O
damaging O
agents O
are O
consistent O
with O
a O
role O
for O
BRCA1 O
in O
DNA O
repair O
. O

Here O
, O
it O
is O
shown O
that O
mouse O
embryonic O
stem O
cells O
deficient B
in I
BRCA1 I
are O
defective O
in O
the O
ability O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
oxidative O
DNA O
damage O
, O
and O
are O
hypersensitive O
to O
ionizing O
radiation O
and O
hydrogen O
peroxide O
. O

These O
results O
suggest O
that O
BRCA1 O
participates O
, O
directly O
or O
indirectly O
, O
in O
transcription O
- O
coupled O
repair O
of O
oxidative O
DNA O
damage O
. O
. O

Truncation O
mutations O
in O
the O
transactivation O
region O
of O
PAX6 O
result O
in O
dominant O
- O
negative O
mutants O
. O

PAX6 O
is O
a O
transcription O
factor O
with O
two O
DNA O
- O
binding O
domains O
( O
paired O
box O
and O
homeobox O
) O
and O
a O
proline O
- O
serine O
- O
threonine O
( O
PST O
) O
- O
rich O
transactivation O
domain O
. O

PAX6 O
regulates O
eye O
development O
in O
animals O
ranging O
from O
jellyfish O
to O
Drosophila O
to O
humans O
. O

Heterozygous O
mutations O
in O
the O
human O
PAX6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B
, O
Peters B
anomaly I
, O
autosomal B
dominant I
keratitis I
, O
and O
familial B
foveal I
dysplasia I
. O

It O
is O
believed O
that O
the O
mutated O
allele O
of O
PAX6 O
produces O
an O
inactive O
protein O
and O
aniridia B
is O
caused O
due O
to O
genetic O
haploinsufficiency O
. O

However O
, O
several O
truncation O
mutations O
have O
been O
found O
to O
occur O
in O
the O
C O
- O
terminal O
half O
of O
PAX6 O
in O
patients O
with O
Aniridia B
resulting O
in O
mutant O
proteins O
that O
retain O
the O
DNA O
- O
binding O
domains O
but O
have O
lost O
most O
of O
the O
transactivation O
domain O
. O

It O
is O
not O
clear O
whether O
such O
mutants O
really O
behave O
as O
loss O
- O
of O
- O
function O
mutants O
as O
predicted O
by O
haploinsufficiency O
. O

Contrary O
to O
this O
theory O
, O
our O
data O
showed O
that O
these O
mutants O
are O
dominant O
- O
negative O
in O
transient O
transfection O
assays O
when O
they O
are O
coexpressed O
with O
wild O
- O
type O
PAX6 O
. O

We O
found O
that O
the O
dominant O
- O
negative O
effects O
result O
from O
the O
enhanced O
DNA O
binding O
ability O
of O
these O
mutants O
. O

Kinetic O
studies O
of O
binding O
and O
dissociation O
revealed O
that O
various O
truncation O
mutants O
have O
3 O
- O
5 O
- O
fold O
higher O
affinity O
to O
various O
DNA O
- O
binding O
sites O
when O
compared O
with O
the O
wild O
- O
type O
PAX6 O
. O

These O
results O
provide O
a O
new O
insight O
into O
the O
role O
of O
mutant O
PAX6 O
in O
causing O
aniridia B
. O
. O

Reversal O
of O
severe O
hypertrophic B
cardiomyopathy I
and O
excellent O
neuropsychologic O
outcome O
in O
very B
- I
long I
- I
chain I
acyl I
- I
coenzyme I
A I
dehydrogenase I
deficiency I
. O

Very B
- I
long I
- I
chain I
acyl I
- I
coenzyme I
A I
dehydrogenase I
( I
VLCAD I
) I
deficiency I
is O
a O
disorder O
of O
fatty O
acid O
beta O
oxidation O
that O
reportedly O
has O
high O
rates O
of O
morbidity O
and O
mortality O
. O

We O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
VLCAD B
deficiency I
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B
cardiomyopathy I
, O
hepatomegaly B
, O
encephalopathy B
, O
and O
hypotonia B
. O

Biochemical O
studies O
indicated O
VLCAD B
deficiency I
caused O
by O
a O
stable O
yet O
inactive O
enzyme O
. O

Molecular O
genetic O
analysis O
of O
her O
VLCAD O
gene O
revealed O
a O
T1372C O
( O
F458L O
) O
missense O
mutation O
and O
a O
1668 O
ACAG O
1669 O
splice O
site O
mutation O
. O

After O
initial O
treatment O
with O
intravenous O
glucose O
and O
carnitine O
, O
the O
patient O
has O
thrived O
on O
a O
low O
- O
fat O
diet O
supplemented O
with O
medium O
- O
chain O
triglyceride O
oil O
and O
carnitine O
and O
avoidance O
of O
fasting O
. O

Her O
ventricular O
hypertrophy O
resolved O
significantly O
over O
1 O
year O
, O
and O
cognitively O
, O
she O
is O
in O
the O
superior O
range O
for O
age O
. O

Clinical O
recognition O
of O
VLCAD B
deficiency I
is O
important O
because O
it O
is O
one O
of O
the O
few O
directly O
treatable O
causes O
of O
cardiomyopathy B
in O
children O
. O
. O

Cloning O
of O
a O
novel O
member O
of O
the O
low O
- O
density O
lipoprotein O
receptor O
family O
. O

A O
gene O
encoding O
a O
novel O
transmembrane O
protein O
was O
identified O
by O
DNA O
sequence O
analysis O
within O
the O
insulin B
- I
dependent I
diabetes I
mellitus I
( O
IDDM B
) O
locus O
IDDM4 O
on O
chromosome O
11q13 O
. O

Based O
on O
its O
chromosomal O
position O
, O
this O
gene O
is O
a O
candidate O
for O
conferring O
susceptibility O
to O
diabetes B
. O

The O
gene O
, O
termed O
low O
- O
density O
lipoprotein O
receptor O
related O
protein O
5 O
( O
LRP5 O
) O
, O
encodes O
a O
protein O
of O
1615 O
amino O
acids O
that O
contains O
conserved O
modules O
which O
are O
characteristic O
of O
the O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
receptor O
family O
. O

These O
modules O
include O
a O
putative O
signal O
peptide O
for O
protein O
export O
, O
four O
epidermal O
growth O
factor O
( O
EGF O
) O
repeats O
with O
associated O
spacer O
domains O
, O
three O
LDL O
- O
receptor O
( O
LDLR O
) O
repeats O
, O
a O
single O
transmembrane O
spanning O
domain O
, O
and O
a O
cytoplasmic O
domain O
. O

The O
encoded O
protein O
has O
a O
unique O
organization O
of O
EGF O
and O
LDLR O
repeats O
; O
therefore O
, O
LRP5 O
likely O
represents O
a O
new O
category O
of O
the O
LDLR O
family O
. O

Both O
human O
and O
mouse O
LRP5 O
cDNAs O
have O
been O
isolated O
and O
the O
encoded O
mature O
proteins O
are O
95 O
% O
identical O
, O
indicating O
a O
high O
degree O
of O
evolutionary O
conservation O
. O
. O

The O
APC B
variants O
I1307K O
and O
E1317Q O
are O
associated O
with O
colorectal B
tumors I
, O
but O
not O
always O
with O
a O
family O
history O
. O

Classical O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
high O
- O
penetrance O
autosomal B
dominant I
disease I
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B
adenomas I
and I
carcinoma I
and O
that O
results O
from O
truncating O
mutations O
in O
the O
APC B
gene O
. O

A O
variant O
of O
FAP B
is O
attenuated B
adenomatous I
polyposis I
coli I
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
APC B
gene O
. O

Attenuated B
adenomatous I
polyposis I
coli I
patients O
have O
" O
multiple O
" O
colorectal B
adenomas I
( O
typically O
fewer O
than O
100 O
) O
without O
the O
florid O
phenotype O
of O
classical O
FAP B
. O

Another O
group O
of O
patients O
with O
multiple O
adenomas B
has O
no O
mutations O
in O
the O
APC B
gene O
, O
and O
their O
phenotype O
probably O
results O
from O
variation O
at O
a O
locus O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O

Recently O
, O
however O
, O
a O
missense O
variant O
of O
APC B
( O
I1307K O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B
tumors I
, O
including O
multiple O
adenomas B
, O
in O
Ashkenazim O
. O

We O
have O
studied O
a O
set O
of O
164 O
patients O
with O
multiple O
colorectal B
adenomas I
and I
/ I
or I
carcinoma I
and O
analyzed O
codons O
1263 O
- O
1377 O
( O
exon O
15G O
) O
of O
the O
APC B
gene O
for O
germ O
- O
line O
variants O
. O

Three O
patients O
with O
the O
I1307K O
allele O
were O
detected O
, O
each O
of O
Ashkenazi O
descent O
. O

Four O
patients O
had O
a O
germ O
- O
line O
E1317Q O
missense O
variant O
of O
APC O
that O
was O
not O
present O
in O
controls O
; O
one O
of O
these O
individuals O
had O
an O
unusually O
large O
number O
of O
metaplastic B
polyps I
of I
the I
colorectum I
. O

There O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
APC B
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B
adenomas I
and I
carcinoma I
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
FAP B
, O
and O
possibly O
with O
importance O
for O
colorectal B
cancer I
risk O
in O
the O
general O
population O
. O
. O

Genomic O
structure O
of O
the O
human O
congenital B
chloride I
diarrhea I
( O
CLD B
) O
gene O
. O

Congenital B
chloride I
diarrhea I
( O
CLD B
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
encodes O
an O
intestinal O
anion O
transporter O
. O

We O
report O
here O
the O
complete O
genomic O
organization O
of O
the O
human O
CLD B
gene O
which O
spans O
approximately O
39kb O
, O
and O
comprises O
21 O
exons O
. O

All O
exon O
/ O
intron O
boundaries O
conform O
to O
the O
GT O
/ O
AG O
rule O
. O

An O
analysis O
of O
the O
putative O
promoter O
region O
sequence O
shows O
a O
putative O
TATA O
box O
and O
predicts O
multiple O
transcription O
factor O
binding O
sites O
. O

The O
genomic O
structure O
was O
determined O
using O
DNA O
from O
several O
sources O
including O
multiple O
large O
- O
insert O
libaries O
and O
genomic O
DNA O
from O
Finnish O
CLD B
patients O
and O
controls O
. O

Exon O
- O
specific O
primers O
developed O
in O
this O
study O
will O
facilitate O
mutation O
screening O
studies O
of O
patients O
with O
the O
disease O
. O

Genomic O
sequencing O
of O
a O
BAC O
clone O
H O
_ O
RG364P16 O
revealed O
the O
presence O
of O
another O
, O
highly O
homologous O
gene O
3 O
of O
the O
CLD B
gene O
, O
with O
a O
similar O
genomic O
structure O
, O
recently O
identified O
as O
the O
Pendred B
syndrome I
gene O
( O
PDS B
) O
. O
. O

The O
APCI1307K O
allele O
and O
cancer B
risk O
in O
a O
community O
- O
based O
study O
of O
Ashkenazi O
Jews O
. O

Mutations O
in O
APC O
are O
classically O
associated O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
a O
highly O
penetrant O
autosomal B
dominant I
disorder I
characterized O
by O
multiple O
intestinal O
polyps B
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B
cancer I
( O
CRC B
) O
. O

APC B
is O
a O
tumour O
- O
suppressor O
gene O
, O
and O
somatic O
loss O
occurs O
in O
tumours B
. O

The O
germline O
T O
- O
to O
- O
A O
transversion O
responsible O
for O
the O
APC O
I1307K O
allele O
converts O
the O
wild O
- O
type O
sequence O
to O
a O
homopolymer O
tract O
( O
A8 O
) O
that O
is O
genetically O
unstable O
and O
prone O
to O
somatic O
mutation O
. O

The O
I1307K O
allele O
was O
found O
in O
6 O
. O

1 O
% O
of O
unselected O
Ashkenazi O
Jews O
and O
higher O
proportions O
of O
Ashkenazim O
with O
family O
or O
personal O
histories O
of O
CRC B
( O
ref O
. O
2 O
) O
. O

To O
evaluate O
the O
role O
of O
I1307K O
in O
cancer B
, O
we O
genotyped O
5 O
, O
081 O
Ashkenazi O
volunteers O
in O
a O
community O
survey O
. O

Risk O
of O
developing O
colorectal B
, I
breast I
and I
other I
cancers I
were O
compared O
between O
genotyped O
I1307K O
carriers O
and O
non O
- O
carriers O
and O
their O
first O
- O
degree O
relatives O
. O

Sperm O
DNA O
analysis O
in O
a O
Friedreich B
ataxia I
premutation O
carrier O
suggests O
both O
meiotic O
and O
mitotic O
expansion O
in O
the O
FRDA B
gene O
. O

Friedreich B
ataxia I
is O
usually O
caused O
by O
an O
expansion O
of O
a O
GAA O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
FRDA B
gene O
. O

Occasionally O
, O
a O
fully O
expanded O
allele O
has O
been O
found O
to O
arise O
from O
a O
premutation O
of O
100 O
or O
less O
triplet O
repeats O
. O

We O
have O
examined O
the O
sperm O
DNA O
of O
a O
premutation O
carrier O
. O

This O
mans O
leucocyte O
DNA O
showed O
one O
normal O
allele O
and O
one O
allele O
of O
approximately O
100 O
repeats O
. O

His O
sperm O
showed O
an O
expanded O
allele O
in O
a O
tight O
range O
centering O
on O
a O
size O
of O
approximately O
320 O
trinucleotide O
repeats O
. O

His O
affected O
son O
has O
repeat O
sizes O
of O
1040 O
and O
540 O
. O

These O
data O
suggest O
that O
expansion O
occurs O
in O
two O
stages O
, O
the O
first O
during O
meiosis O
followed O
by O
a O
second O
mitotic O
expansion O
. O

We O
also O
show O
that O
in O
all O
informative O
carrier O
father O
to O
affected O
child O
transmissions O
, O
with O
the O
notable O
exception O
of O
the O
premutation O
carrier O
, O
the O
expansion O
size O
decreases O
. O
. O

The O
R496H O
mutation O
of O
arylsulfatase O
A O
does O
not O
cause O
metachromatic B
leukodystrophy I
. O

Deficiency B
of I
arylsulfatase I
A I
( O
ARSA O
) O
enzyme O
activity O
causes O
metachromatic B
leukodystrophy I
( O
MLD B
) O
. O

A O
number O
of O
ARSA O
gene O
mutations O
responsible O
for O
MLD B
have O
been O
identified O
. O

Recently O
, O
the O
R496H O
mutation O
of O
ARSA O
was O
proposed O
to O
be O
a O
cause O
of O
MLD B
( O
Draghia O
et O
al O
. O
, O
1997 O
) O
. O

We O
have O
investigated O
the O
R496H O
mutation O
and O
found O
this O
mutation O
at O
a O
relatively O
high O
frequency O
in O
an O
African O
American O
population O
( O
f O
= O
0 O
. O
09 O
, O
n O
= O
61 O
subjects O
) O
. O

The O
ARSA O
enzyme O
activity O
in O
subjects O
with O
and O
without O
the O
R496H O
mutation O
was O
determined O
and O
found O
to O
be O
normal O
. O

It O
is O
therefore O
concluded O
that O
the O
R496H O
mutation O
of O
ARSA O
does O
not O
negatively O
influence O
the O
activity O
of O
ARSA O
and O
is O
not O
a O
cause O
of O
MLD B

Down O
- O
regulation O
of O
transmembrane O
carbonic O
anhydrases O
in O
renal B
cell I
carcinoma I
cell O
lines O
by O
wild O
- O
type O
von B
Hippel I
- I
Lindau I
transgenes O
. O

To O
discover O
genes O
involved O
in O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B
cell I
carcinoma I
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
VHL O
- O
expressing O
transgenes O
. O

Large O
- O
scale O
RNA O
differential O
display O
technology O
applied O
to O
these O
cell O
lines O
identified O
several O
differentially O
expressed O
genes O
, O
including O
an O
alpha O
carbonic O
anhydrase O
gene O
, O
termed O
CA12 O
. O

The O
deduced O
protein O
sequence O
was O
classified O
as O
a O
one O
- O
pass O
transmembrane O
CA O
possessing O
an O
apparently O
intact O
catalytic O
domain O
in O
the O
extracellular O
CA O
module O
. O

Reintroduced O
wild O
- O
type O
VHL B
strongly O
inhibited O
the O
overexpression O
of O
the O
CA12 O
gene O
in O
the O
parental O
renal B
cell I
carcinoma I
cell O
lines O
. O

Similar O
results O
were O
obtained O
with O
CA9 O
, O
encoding O
another O
transmembrane O
CA O
with O
an O
intact O
catalytic O
domain O
. O

Although O
both O
domains O
of O
the O
VHL B
protein O
contribute O
to O
regulation O
of O
CA12 O
expression O
, O
the O
elongin O
binding O
domain O
alone O
could O
effectively O
regulate O
CA9 O
expression O
. O

We O
mapped O
CA12 O
and O
CA9 O
loci O
to O
chromosome O
bands O
15q22 O
and O
17q21 O
. O

2 O
respectively O
, O
regions O
prone O
to O
amplification O
in O
some O
human O
cancers B
. O

Additional O
experiments O
are O
needed O
to O
define O
the O
role O
of O
CA O
IX O
and O
CA O
XII O
enzymes O
in O
the O
regulation O
of O
pH O
in O
the O
extracellular O
microenvironment O
and O
its O
potential O
impact O
on O
cancer B
cell O
growth O
. O

A O
gene O
encoding O
a O
transmembrane O
protein O
is O
mutated O
in O
patients O
with O
diabetes B
mellitus I
and O
optic B
atrophy I
( O
Wolfram B
syndrome I
) O
. O

Wolfram B
syndrome I
( O
WFS B
; O
OMIM O
222300 O
) O
is O
an O
autosomal B
recessive I
neurodegenerative I
disorder I
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B
- I
dependent I
diabetes I
mellitus I
and O
progressive O
optic B
atrophy I
. O

Linkage O
to O
markers O
on O
chromosome O
4p O
was O
confirmed O
in O
five O
families O
. O

On O
the O
basis O
of O
meiotic O
recombinants O
and O
disease O
- O
associated O
haplotypes O
, O
the O
WFS B
gene O
was O
localized O
to O
a O
BAC O
/ O
P1 O
contig O
of O
less O
than O
250 O
kb O
. O

Mutations O
in O
a O
novel O
gene O
( O
WFS1 O
) O
encoding O
a O
putative O
transmembrane O
protein O
were O
found O
in O
all O
affected O
individuals O
in O
six O
WFS B
families O
, O
and O
these O
mutations O
were O
associated O
with O
the O
disease O
phenotype O
. O

WFS1 O
appears O
to O
function O
in O
survival O
of O
islet O
beta O
- O
cells O
and O
neurons O
. O
. O

Stable O
interaction O
between O
the O
products O
of O
the O
BRCA1 O
and O
BRCA2 O
tumor B
suppressor O
genes O
in O
mitotic O
and O
meiotic O
cells O
. O

BRCA1 O
and O
BRCA2 O
account O
for O
most O
cases O
of O
familial O
, O
early O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
encode O
products O
that O
each O
interact O
with O
hRAD51 O
. O

Results O
presented O
here O
show O
that O
BRCA1 O
and O
BRCA2 O
coexist O
in O
a O
biochemical O
complex O
and O
colocalize O
in O
subnuclear O
foci O
in O
somatic O
cells O
and O
on O
the O
axial O
elements O
of O
developing O
synaptonemal O
complexes O
. O

Like O
BRCA1 O
and O
RAD51 O
, O
BRCA2 O
relocates O
to O
PCNA O
+ O
replication O
sites O
following O
exposure O
of O
S O
phase O
cells O
to O
hydroxyurea O
or O
UV O
irradiation O
. O

Thus O
, O
BRCA1 O
and O
BRCA2 O
participate O
, O
together O
, O
in O
a O
pathway O
( O
s O
) O
associated O
with O
the O
activation O
of O
double O
- O
strand O
break O
repair O
and O
/ O
or O
homologous O
recombination O
. O

Dysfunction O
of O
this O
pathway O
may O
be O
a O
general O
phenomenon O
in O
the O
majority O
of O
cases O
of O
hereditary B
breast I
and I
/ I
or I
ovarian I
cancer I
. O
. O

A O
novel O
Arg362Ser O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
CYP27 O
) O
: O
its O
effects O
on O
pre O
- O
mRNA O
splicing O
and O
enzyme O
activity O
. O

A O
novel O
C O
to O
A O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
CYP27 O
) O
was O
identified O
by O
sequencing O
amplified O
CYP27 O
gene O
products O
from O
a O
patient O
with O
cerebrotendinous B
xanthomatosis I
( O
CTX B
) O
. O

The O
mutation O
changed O
the O
adrenodoxin O
cofactor O
binding O
residue O
362Arg O
to O
362Ser O
( O
CGT O
362Arg O
to O
AGT O
362Ser O
) O
, O
and O
was O
responsible O
for O
deficiency O
in O
the O
sterol O
27 O
- O
hydroxylase O
activity O
, O
as O
confirmed O
by O
expression O
of O
mutant O
cDNA O
into O
COS O
- O
1 O
cells O
. O

Quantitative O
analysis O
showed O
that O
the O
expression O
of O
CYP27 O
gene O
mRNA O
in O
the O
patient O
represented O
52 O
. O

5 O
% O
of O
the O
normal O
level O
. O

As O
the O
mutation O
occurred O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
( O
- O
2 O
position O
of O
exon O
6 O
- O
intron O
6 O
splice O
site O
) O
of O
the O
gene O
, O
we O
hypothesized O
that O
the O
mutation O
may O
partially O
affect O
the O
normal O
splicing O
efficiency O
in O
exon O
6 O
and O
cause O
alternative O
splicing O
elsewhere O
, O
which O
resulted O
in O
decreased O
transcript O
in O
the O
patient O
. O

Transfection O
of O
constructed O
minigenes O
, O
with O
or O
without O
the O
mutation O
, O
into O
COS O
- O
1 O
cells O
confirmed O
that O
the O
mutant O
minigene O
was O
responsible O
for O
a O
mRNA O
species O
alternatively O
spliced O
at O
an O
activated O
cryptic O
5 O
splice O
site O
88 O
bp O
upstream O
from O
the O
3 O
end O
of O
exon O
6 O
. O

Our O
data O
suggest O
that O
the O
C O
to O
A O
mutation O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
of O
the O
CYP27 O
gene O
not O
only O
causes O
the O
deficiency B
in I
the I
sterol I
27 I
- I
hydroxylase I
activity I
, O
but O
also O
partially O
leads O
to O
alternative O
pre O
- O
mRNA O
splicing O
of O
the O
gene O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
regarding O
effects O
on O
pre O
- O
mRNA O
splicing O
of O
a O
mutation O
at O
the O
- O
2 O
position O
of O
a O
5 O
splice O
site O
. O

ATM O
germline O
mutations O
in O
classical O
ataxia B
- I
telangiectasia I
patients O
in O
the O
Dutch O
population O
. O

Germline O
mutations O
in O
the O
ATM O
gene O
are O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
. O

In O
our O
study O
, O
we O
have O
determined O
the O
ATM O
mutation O
spectrum O
in O
19 O
classical O
A B
- I
T I
patients O
, O
including O
some O
immigrant O
populations O
, O
as O
well O
as O
12 O
of O
Dutch O
ethnic O
origin O
. O

Both O
the O
protein O
truncation O
test O
( O
PTT O
) O
and O
the O
restriction O
endonuclease O
fingerprinting O
( O
REF O
) O
method O
were O
used O
and O
compared O
for O
their O
detection O
efficiency O
, O
identifying O
76 O
% O
and O
60 O
% O
of O
the O
mutations O
, O
respectively O
. O

Most O
patients O
were O
found O
to O
be O
compound O
heterozygote O
. O

Seventeen O
mutations O
were O
distinct O
, O
of O
which O
10 O
were O
not O
reported O
previously O
. O

Mutations O
are O
small O
deletions O
or O
point O
mutations O
frequently O
affecting O
splice O
sites O
. O

Moreover O
, O
a O
16 O
. O

7 O
- O
kb O
genomic O
deletion O
of O
the O
3 O
end O
of O
the O
gene O
, O
most O
likely O
a O
result O
of O
recombination O
between O
two O
LINE O
elements O
, O
was O
identified O
. O

The O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
Turkish O
A B
- I
T I
individuals O
, O
was O
previously O
described O
to O
be O
a O
Turkish O
A B
- I
T I
founder O
mutation O
. O

The O
presence O
of O
a O
founder O
mutation O
among O
relatively O
small O
ethnic O
population O
groups O
in O
Western O
Europe O
could O
indicate O
a O
high O
carrier O
frequency O
in O
such O
communities O
. O

In O
patients O
of O
Dutch O
ethnic O
origin O
, O
however O
, O
no O
significant O
founder O
effect O
could O
be O
identified O
. O

The O
observed O
genetic O
heterogeneity O
including O
the O
relative O
high O
percentage O
of O
splice O
- O
site O
mutations O
had O
no O
reflection O
on O
the O
phenotype O
. O

All O
patients O
manifested O
classical O
A B
- I
T I
and O
increased O
cellular O
radioresistant O
DNA O
synthesis O
. O

Determination O
of O
the O
genomic O
structure O
of O
the O
COL4A4 O
gene O
and O
of O
novel O
mutations O
causing O
autosomal B
recessive I
Alport I
syndrome I
. O

Autosomal B
recessive I
Alport I
syndrome I
is O
a O
progressive O
hematuric B
glomerulonephritis I
characterized O
by O
glomerular B
basement I
membrane I
abnormalities I
and O
associated O
with O
mutations O
in O
either O
the O
COL4A3 O
or O
the O
COL4A4 O
gene O
, O
which O
encode O
the O
alpha3 O
and O
alpha4 O
type O
IV O
collagen O
chains O
, O
respectively O
. O

To O
date O
, O
mutation O
screening O
in O
the O
two O
genes O
has O
been O
hampered O
by O
the O
lack O
of O
genomic O
structure O
information O
. O

We O
report O
here O
the O
complete O
characterization O
of O
the O
48 O
exons O
of O
the O
COL4A4 O
gene O
, O
a O
comprehensive O
gene O
screen O
, O
and O
the O
subsequent O
detection O
of O
10 O
novel O
mutations O
in O
eight O
patients O
diagnosed O
with O
autosomal B
recessive I
Alport I
syndrome I
. O

Furthermore O
, O
we O
identified O
a O
glycine O
to O
alanine O
substitution O
in O
the O
collagenous O
domain O
that O
is O
apparently O
silent O
in O
the O
heterozygous O
carriers O
, O
in O
11 O
. O

5 O
% O
of O
all O
control O
individuals O
, O
and O
in O
one O
control O
individual O
homozygous O
for O
this O
glycine O
substitution O
. O

There O
has O
been O
no O
previous O
finding O
of O
a O
glycine O
substitution O
that O
is O
not O
associated O
with O
any O
obvious O
phenotype O
in O
homozygous O
individuals O
. O

Founder O
BRCA1 O
and O
BRCA2 O
mutations O
in O
French O
Canadian O
breast B
and I
ovarian I
cancer I
families O
. O

We O
have O
identified O
four O
mutations O
in O
each O
of O
the O
breast B
cancer I
- O
susceptibility O
genes O
, O
BRCA1 O
and O
BRCA2 O
, O
in O
French O
Canadian O
breast B
cancer I
and O
breast B
/ I
ovarian I
cancer I
families O
from O
Quebec O
. O

To O
identify O
founder O
effects O
, O
we O
examined O
independently O
ascertained O
French O
Canadian O
cancer B
families O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O

Mutations O
were O
found O
in O
41 O
of O
97 O
families O
. O

Six O
of O
eight O
mutations O
were O
observed O
at O
least O
twice O
. O

The O
BRCA1 O
C4446T O
mutation O
was O
the O
most O
common O
mutation O
found O
, O
followed O
by O
the O
BRCA2 O
8765delAG O
mutation O
. O

Together O
, O
these O
mutations O
were O
found O
in O
28 O
of O
41 O
families O
identified O
to O
have O
a O
mutation O
. O

The O
odds O
of O
detection O
of O
any O
of O
the O
four O
BRCA1 O
mutations O
was O
18 O
. O

7x O
greater O
if O
one O
or O
more O
cases O
of O
ovarian B
cancer I
were O
also O
present O
in O
the O
family O
. O

The O
odds O
of O
detection O
of O
any O
of O
the O
four O
BRCA2 O
mutations O
was O
5 O
. O

3x O
greater O
if O
there O
were O
at O
least O
five O
cases O
of O
breast B
cancer I
in O
the O
family O
. O

Interestingly O
, O
the O
presence O
of O
a O
breast B
cancer I
case O
< O
36 O
years O
of O
age O
was O
strongly O
predictive O
of O
the O
presence O
of O
any O
of O
the O
eight O
mutations O
screened O
. O

Carriers O
of O
the O
same O
mutation O
, O
from O
different O
families O
, O
shared O
similar O
haplotypes O
, O
indicating O
that O
the O
mutant O
alleles O
were O
likely O
to O
be O
identical O
by O
descent O
for O
a O
mutation O
in O
the O
founder O
population O
. O

The O
identification O
of O
common O
BRCA1 O
and O
BRCA2 O
mutations O
will O
facilitate O
carrier O
detection O
in O
French O
Canadian O
breast B
cancer I
and O
breast B
/ I
ovarian I
cancer I
families O
. O

Are O
Dp71 O
and O
Dp140 O
brain O
dystrophin O
isoforms O
related O
to O
cognitive B
impairment I
in O
Duchenne B
muscular I
dystrophy I
? O

Molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B
impairment I
observed O
in O
most O
DMD B
patients O
. O

Complete O
analysis O
of O
the O
dystrophin O
gene O
was O
performed O
to O
define O
the O
localization O
of O
deletions O
and O
duplications O
in O
relation O
to O
the O
different O
DMD B
promoters O
. O

Qualitative O
analysis O
of O
the O
Dp71 O
transcript O
and O
testing O
for O
the O
specific O
first O
exon O
of O
Dp140 O
were O
also O
carried O
out O
. O

Neuropsychological O
analysis O
assessed O
verbal O
and O
visuospatial O
intelligence O
, O
verbal O
memory O
, O
and O
reading O
skills O
. O

Comparison O
of O
molecular O
and O
psychometric O
findings O
demonstrated O
that O
deletions O
and O
duplications O
that O
were O
localized O
in O
the O
distal O
part O
of O
the O
gene O
seemed O
to O
be O
preferentially O
associated O
with O
cognitive B
impairment I
. O

Two O
altered O
Dp71 O
transcripts O
and O
two O
deleted O
Dp140 O
DNA O
sequences O
were O
found O
in O
four O
patients O
with O
severe O
cerebral B
dysfunction I
. O

These O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
distal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
DMD B
isoforms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B
impairment I
associated O
with O
DMD B
. O
. O

I1307K O
APC O
and O
hMLH1 O
mutations O
in O
a O
non O
- O
Jewish O
family O
with O
hereditary B
non I
- I
polyposis I
colorectal I
cancer I
. O

We O
describe O
a O
French O
Canadian O
hereditary B
non I
- I
polyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindred O
which O
carries O
a O
novel O
truncating O
mutation O
in O
hMLH1 O
. O

Interestingly O
, O
the O
I1307K O
APC O
polymorphism O
, O
associated O
with O
an O
increased O
risk O
of O
colorectal B
cancer I
, O
is O
also O
present O
in O
this O
family O
. O

The O
I1307K O
polymorphism O
has O
previously O
only O
been O
identified O
in O
individuals O
of O
self O
- O
reported O
Ashkenazi O
Jewish O
origins O
. O

In O
addition O
, O
in O
this O
family O
, O
there O
appears O
to O
be O
no O
relationship O
between O
the O
I1307K O
polymorphism O
and O
the O
presence O
or O
absence O
of O
cancer B
. O
. O

Identification O
of O
a O
novel O
mutation O
of O
the O
CPO O
gene O
in O
a O
Japanese O
hereditary B
coproporphyria I
family O
. O

Hereditary B
coproporphyria I
( O
HCP B
) O
is O
an O
autosomal B
dominant I
disease I
characterized O
by O
a O
deficiency B
of I
coproporphyrinogen I
oxidase I
( O
CPO O
) O
caused O
by O
a O
mutation O
in O
the O
CPO O
gene O
. O

Only O
11 O
mutations O
of O
the O
gene O
have O
been O
reported O
in O
HCP B
patients O
. O

We O
report O
another O
mutation O
in O
a O
Japanese O
family O
. O

Polymerase O
chain O
reaction O
- O
single O
strand O
conformational O
polymorphism O
and O
direct O
sequence O
analyses O
demonstrated O
a O
C O
to O
T O
substitution O
in O
exon O
1 O
of O
the O
CPO O
gene O
at O
nucleotide O
position O
85 O
, O
which O
lies O
in O
the O
putative O
presequence O
for O
targeting O
to O
mitochondria O
. O

This O
mutation O
changes O
the O
codon O
for O
glutamine O
to O
a O
termination O
codon O
at O
amino O
acid O
position O
29 O
. O

MaeI O
restriction O
analysis O
showed O
two O
other O
carriers O
in O
the O
family O
. O

The O
C O
- O
T O
mutation O
is O
located O
within O
a O
recently O
proposed O
putative O
alternative O
translation O
initiation O
codon O
( O
TIC O
- O
1 O
) O
, O
supporting O
that O
TIC O
- O
1 O
is O
the O
real O
TIC O
rather O
than O
TIC O
- O
2 O
. O
. O

Human B
complement I
factor I
H I
deficiency I
associated O
with O
hemolytic B
uremic I
syndrome I
. O

This O
study O
reports O
on O
six O
cases O
of O
deficiency B
in I
the I
human I
complement I
regulatory I
protein I
Factor I
H I
( O
FH O
) O
in O
the O
context O
of O
an O
acute B
renal I
disease I
. O

Five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
idiopathic O
hemolytic B
uremic I
syndrome I
( O
HUS B
) O
. O

Two O
of O
the O
children O
exhibited O
a O
homozygous O
deficiency O
characterized O
by O
the O
absence O
of O
the O
150 O
- O
kD O
form O
of O
Factor O
H O
and O
the O
presence O
, O
upon O
immunoblotting O
, O
of O
the O
42 O
- O
kD O
Factor O
H O
- O
like O
protein O
1 O
( O
FHL O
- O
1 O
) O
and O
other O
FH O
- O
related O
protein O
( O
FHR O
) O
bands O
. O

Southern O
blot O
and O
PCR O
analysis O
of O
DNA O
of O
one O
patient O
with O
homozygous O
deficiency O
ruled O
out O
the O
presence O
of O
a O
large O
deletion O
of O
the O
FH O
gene O
as O
the O
underlying O
defect O
for O
the O
deficiency O
. O

The O
other O
four O
children O
presented O
with O
heterozygous O
deficiency O
and O
exhibited O
a O
normal O
immunoblotting O
pattern O
of O
proteins O
of O
the O
FH O
family O
. O

Factor B
H I
deficiency I
is O
the O
only O
complement B
deficiency I
associated O
with O
HUS B
. O

These O
observations O
suggest O
a O
role O
for O
FH O
and O
/ O
or O
FH O
receptors O
in O
the O
pathogenesis O
of O
idiopathic O
HUS B
. O
. O

Further O
evidence O
for O
a O
major O
ancient O
mutation O
underlying O
myotonic B
dystrophy I
from O
linkage O
disequilibrium O
studies O
in O
the O
Japanese O
population O
. O

The O
myotonic B
dystrophy I
( O
DM B
) O
mutation O
is O
an O
unstable O
( O
CTG O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosomes O
but O
amplified O
to O
50 O
- O
3000 O
copies O
on O
DM B
chromosomes O
. O

Previous O
findings O
in O
Caucasian O
populations O
of O
a O
DM B
founder O
chromosome O
raise O
a O
question O
about O
the O
molecular O
events O
involved O
in O
the O
expansion O
mutation O
. O

To O
investigate O
whether O
a O
founder O
chromosome O
for O
the O
DM B
mutation O
exists O
in O
the O
Japanese O
population O
, O
we O
genotyped O
families O
using O
polymorphic O
markers O
near O
the O
( O
CTG O
) O
n O
repeat O
region O
and O
constructed O
haplotypes O
. O

Six O
different O
haplotypes O
were O
found O
and O
DM B
alleles O
were O
always O
haplotype O
A O
. O

To O
find O
an O
origin O
of O
the O
( O
CTG O
) O
n O
repeat O
mutation O
and O
to O
investigate O
the O
mechanism O
of O
the O
expansion O
mutation O
in O
the O
Japanese O
population O
we O
have O
studied O
90 O
Japanese O
DM B
families O
comprising O
190 O
affected O
and O
130 O
unaffected O
members O
. O

The O
results O
suggest O
that O
a O
few O
common O
ancestral O
mutations O
in O
both O
Caucasian O
and O
Japanese O
populations O
have O
originated O
by O
expansion O
of O
an O
ancestral O
n O
= O
5 O
repeat O
to O
n O
= O
19 O
- O
37 O
copies O
. O

These O
data O
support O
multistep O
models O
of O
triplet O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
DM B
and O
Friedreichs B
ataxia I
. O
. O

The O
molecular O
basis O
of O
C6 B
deficiency I
in O
the O
western O
Cape O
, O
South O
Africa O
. O

Deficiency B
of I
the I
sixth I
component I
of I
human I
complement I
( O
C6 O
) O
has O
been O
reported O
in O
a O
number O
of O
families O
from O
the O
western O
Cape O
, O
South O
Africa O
. O

Meningococcal B
disease I
is O
endemic O
in O
the O
Cape O
and O
almost O
all O
pedigrees O
of O
total O
C6 B
deficiency I
( O
C6Q0 O
) O
have O
been O
ascertained O
because O
of O
recurrent O
disease O
. O

We O
have O
sequenced O
the O
expressed O
exons O
of O
the O
C6 O
gene O
from O
selected O
cases O
and O
have O
found O
three O
molecular O
defects O
leading O
to O
total O
deficiency O
879delG O
, O
which O
is O
the O
common O
defect O
in O
the O
Cape O
and O
hitherto O
unreported O
, O
and O
1195delC O
and O
1936delG O
, O
which O
have O
been O
previously O
reported O
in O
African O
- O
Americans O
. O

We O
also O
show O
that O
the O
879delG O
and O
1195delC O
defects O
are O
associated O
with O
characteristic O
C6 O
/ O
C7 O
region O
DNA O
marker O
haplotypes O
, O
although O
small O
variations O
were O
observed O
. O

The O
1936delG O
defect O
was O
observed O
only O
once O
in O
the O
Cape O
, O
but O
its O
associated O
haplotype O
could O
be O
deduced O
. O

The O
data O
from O
the O
haplotypes O
indicate O
that O
these O
three O
molecular O
defects O
account O
for O
the O
defects O
in O
all O
the O
38 O
unrelated O
C6Q0 O
individuals O
we O
have O
studied O
from O
the O
Cape O
. O

We O
have O
also O
observed O
the O
879delG O
defect O
in O
two O
Dutch O
C6 B
- I
deficient I
kindreds O
, O
but O
the O
879delG O
defect O
in O
the O
Cape O
probably O
did O
not O
come O
from O
The O
Netherlands O
. O
. O

Complement B
C7 I
deficiency I
: O
seven O
further O
molecular O
defects O
and O
their O
associated O
marker O
haplotypes O
. O

Seven O
further O
molecular O
bases O
of O
C7 B
deficiency I
are O
described O
. O

All O
these O
new O
molecular O
defects O
involve O
single O
- O
nucleotide O
events O
, O
deletions O
and O
substitutions O
, O
some O
of O
which O
alter O
splice O
sites O
, O
and O
others O
codons O
. O

They O
are O
distributed O
along O
the O
C7 O
gene O
, O
but O
predominantly O
towards O
the O
3 O
end O
. O

All O
were O
found O
in O
compound O
heterozygous O
individuals O
. O

The O
C6 O
/ O
C7 O
marker O
haplotypes O
associated O
with O
most O
C7 B
defects I
are O
tabulated O
. O
. O

A O
genome O
- O
wide O
search O
for O
chromosomal O
loci O
linked O
to O
mental O
health O
wellness O
in O
relatives O
at O
high O
risk O
for O
bipolar B
affective I
disorder I
among O
the O
Old O
Order O
Amish O
. O

Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
characterized O
by O
episodes O
of O
mania B
and O
/ O
or O
hypomania B
interspersed O
with O
periods O
of O
depression B
. O

Compelling O
evidence O
supports O
a O
significant O
genetic O
component O
in O
the O
susceptibility O
to O
develop O
BPAD B
. O

To O
date O
, O
however O
, O
linkage O
studies O
have O
attempted O
only O
to O
identify O
chromosomal O
loci O
that O
cause O
or O
increase O
the O
risk O
of O
developing O
BPAD B
. O

To O
determine O
whether O
there O
could O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
BPAD B
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B
disorders I
, O
we O
used O
mental O
health O
wellness O
( O
absence O
of O
any O
psychiatric B
disorder I
) O
as O
the O
phenotype O
in O
our O
genome O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
Old O
Order O
Amish O
pedigrees O
exhibiting O
an O
extremely O
high O
incidence O
of O
BPAD B
. O

We O
have O
found O
strong O
evidence O
for O
a O
locus O
on O
chromosome O
4p O
at O
D4S2949 O
( O
maximum O
GENEHUNTER O
- O
PLUS O
nonparametric O
linkage O
score O
= O
4 O
. O
05 O
, O
P O
= O
5 O
. O
22 O
x O
10 O
( O
- O
4 O
) O
; O
SIBPAL O
Pempirical O
value O
< O
3 O
x O
10 O
( O
- O
5 O
) O
) O
and O
suggestive O
evidence O
for O
a O
locus O
on O
chromosome O
4q O
at O
D4S397 O
( O
maximum O
GENEHUNTER O
- O
PLUS O
nonparametric O
linkage O
score O
= O
3 O
. O
29 O
, O
P O
= O
2 O
. O
57 O
x O
10 O
( O
- O
3 O

) O
; O
SIBPAL O
Pempirical O
value O
< O
1 O
x O
10 O
( O
- O
3 O
) O
) O
that O
are O
linked O
to O
mental O
health O
wellness O
. O

These O
findings O
are O
consistent O
with O
the O
hypothesis O
that O
certain O
alleles O
could O
prevent O
or O
modify O
the O
clinical O
manifestations O
of O
BPAD B
and O
perhaps O
other O
related O
affective B
disorders I
. O

Segregation O
distortion O
in O
myotonic B
dystrophy I
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disease I
which O
, O
in O
the O
typical O
pedigree O
, O
shows O
a O
three O
generation O
anticipation O
cascade O
. O

This O
results O
in O
infertility B
and O
congenital B
myotonic I
dystrophy I
( O
CDM B
) O
with O
the O
disappearance O
of O
DM B
in O
that O
pedigree O
. O

The O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
preferential O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B
locus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
DM B
in O
the O
population O
. O

In O
a O
survey O
of O
DM B
in O
Northern O
Ireland O
, O
59 O
pedigrees O
were O
ascertained O
. O

Sibships O
where O
the O
status O
of O
all O
the O
members O
had O
been O
identified O
were O
examined O
to O
determine O
the O
transmission O
of O
the O
DM B
expansion O
from O
affected O
parents O
to O
their O
offspring O
. O

Where O
the O
transmitting O
parent O
was O
male O
, O
58 O
. O

3 O
% O
of O
the O
offspring O
were O
affected O
, O
and O
in O
the O
case O
of O
a O
female O
transmitting O
parent O
, O
68 O
. O

7 O
% O
were O
affected O
. O

Studies O
on O
meiotic O
drive O
in O
DM B
have O
shown O
increased O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B
locus O
in O
non O
- O
DM O
heterozygotes O
for O
CTGn O
. O

This O
study O
provides O
further O
evidence O
that O
the O
DM B
expansion O
tends O
to O
be O
transmitted O
preferentially O
. O

Diagnosis O
of O
hemochromatosis B
. O

If O
untreated O
, O
hemochromatosis B
can O
cause O
serious O
illness O
and O
early B
death I
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
diagnosed O
. O

The O
cornerstone O
of O
screening O
and O
case O
detection O
is O
the O
measurement O
of O
serum O
transferrin O
saturation O
and O
the O
serum O
ferritin O
level O
. O

Once O
the O
diagnosis O
is O
suspected O
, O
physicians O
must O
use O
serum O
ferritin O
levels O
and O
hepatic O
iron O
stores O
on O
liver O
biopsy O
specimens O
to O
assess O
patients O
for O
the O
presence O
of O
iron B
overload I
. O

Liver O
biopsy O
is O
also O
used O
to O
establish O
the O
presence O
or O
absence O
of O
cirrhosis B
, O
which O
can O
affect O
prognosis O
and O
management O
. O

A O
DNA O
- O
based O
test O
for O
the O
HFE O
gene O
is O
commercially O
available O
, O
but O
its O
place O
in O
the O
diagnosis O
of O
hemochromatosis B
is O
still O
being O
evaluated O
. O

Currently O
, O
the O
most O
useful O
role O
for O
this O
test O
is O
in O
the O
detection O
of O
hemochromatosis B
in O
the O
family O
members O
of O
patients O
with O
a O
proven O
case O
of O
the O
disease O
. O

It O
is O
crucial O
to O
diagnose O
hemochromatosis B
before O
hepatic B
cirrhosis I
develops O
because O
phlebotomy O
therapy O
can O
avert O
serious O
chronic O
disease O
and O
can O
even O
lead O
to O
normal O
life O
expectancy O
. O
. O

Prevalence O
of O
the O
I1307K O
APC B
gene O
variant O
in O
Israeli O
Jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B
cancer I
. O

BACKGROUND O
& O
AIMS O
Israeli O
Jews O
of O
European O
birth O
, O
i O
. O
e O
. O
, O
Ashkenazim O
, O
have O
the O
highest O
colorectal B
cancer I
incidence O
of O
any O
Israeli O
ethnic O
group O
. O

The O
I1307K O
APC B
gene O
variant O
was O
found O
in O
6 O
. O

1 O
% O
of O
American O
Jews O
, O
28 O
% O
of O
their O
familial O
colorectal B
cancer I
cases O
, O
but O
not O
in O
non O
- O
Jews O
. O

We O
assessed O
the O
I1307K O
prevalence O
in O
Israeli O
Jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B
cancer I
. O

METHODS O
DNA O
samples O
from O
500 O
unrelated O
Jews O
of O
European O
or O
non O
- O
European O
origin O
, O
with O
or O
without O
a O
personal O
and O
/ O
or O
family O
history O
of O
neoplasia B
, O
were O
examined O
for O
the O
I1307K O
variant O
by O
the O
allele O
- O
specific O
oligonucleotide O
( O
ASO O
) O
method O
. O

RESULTS O
In O
persons O
at O
average O
risk O
for O
colorectal B
cancer I
, O
I1307K O
was O
found O
in O
5 O
. O

0 O
% O
of O
120 O
European O
and O
1 O
. O

6 O
% O
of O
188 O
non O
- O
European O
Jews O
( O
P O
= O
0 O
. O
08 O
) O
. O

It O
occurred O
in O
15 O
. O

4 O
% O
of O
52 O
Ashkenazi O
Israelis O
with O
familial O
cancer B
( O
P O
= O
0 O
. O
02 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
European O
Jews O
at O
increased O
cancer B
risk O
. O

Colorectal B
neoplasia I
occurred O
personally O
or O
in O
the O
families O
of O
13 O
of O
20 O
Ashkenazi O
I1307K O
carriers O
, O
8 O
of O
whom O
also O
had O
a O
personal O
or O
family O
history O
of O
noncolonic O
neoplasia B
. O

CONCLUSIONS O
The O
I1307K O
APC O
variant O
may O
represent O
a O
susceptibility O
gene O
for O
colorectal B
, I
or I
other I
, I
cancers I
in O
Ashkenazi O
Jews O
, O
and O
partially O
explains O
the O
higher O
incidence O
of O
colorectal B
cancer I
in O
European O
Israelis O
. O

Systematic O
analysis O
of O
coproporphyrinogen O
oxidase O
gene O
defects O
in O
hereditary B
coproporphyria I
and O
mutation O
update O
. O

Hereditary B
coproporphyria I
( O
HC B
) O
is O
an O
acute O
hepatic B
porphyria I
with O
autosomal O
dominant O
inheritance O
caused O
by O
deficient B
activity I
of I
coproporphyrinogen I
III I
oxidase I
( O
CPO O
) O
. O

Clinical O
manifestations O
of O
the O
disease O
are O
characterized O
by O
acute O
attacks O
of O
neurological B
dysfunction I
often O
precipitated O
by O
drugs O
, O
fasting O
, O
cyclical O
hormonal O
changes O
, O
or O
infectious B
diseases I
. O

Skin O
photosensitivity O
may O
also O
be O
present O
. O

The O
seven O
exons O
, O
the O
exon O
/ O
intron O
boundaries O
and O
part O
of O
3 O
noncoding O
sequence O
of O
the O
CPO O
gene O
were O
systematically O
analyzed O
by O
an O
exon O
- O
by O
- O
exon O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
strategy O
followed O
by O
direct O
sequencing O
in O
seven O
unrelated O
heterozygous O
HC B
patients O
from O
France O
, O
Holland O
, O
and O
Czech O
Republic O
. O

Seven O
novel O
mutations O
and O
two O
new O
polymorphisms O
were O
detected O
. O

Among O
these O
mutations O
two O
are O
missense O
( O
G197W O
, O
W427R O
) O
, O
two O
are O
nonsense O
( O
Q306X O
, O
Q385X O
) O
, O
two O
are O
small O
deletions O
( O
662de14bp O
; O
1168del3bp O
removing O
a O
glycine O
at O
position O
390 O
) O
, O
and O
one O
is O
a O
splicing O
mutation O
( O
IVS1 O
- O
15c O
- O
- O
> O
g O
) O
which O
creates O
a O
new O
acceptor O
splice O
site O
. O

The O
pathological O
significance O
of O
the O
point O
mutations O
G197W O
, O
W427R O
, O
and O
the O
in O
- O
frame O
deletion O
390delGly O
were O
assessed O
by O
their O
respective O
expression O
in O
a O
prokaryotic O
system O
using O
site O
- O
directed O
mutagenesis O
. O

These O
mutations O
resulted O
in O
the O
absence O
or O
a O
dramatic O
decrease O
of O
CPO O
activity O
. O

The O
two O
polymorphisms O
were O
localized O
in O
noncoding O
part O
of O
the O
gene O
1 O
) O
a O
C O
/ O
G O
polymorphism O
in O
the O
promotor O
region O
, O
142 O
bp O
upstream O
from O
the O
transcriptional O
initiation O
site O
( O
- O
142C O
/ O
G O
) O
, O
and O
2 O
) O
a O
6 O
bp O
deletion O
polymorphism O
in O
the O
3 O
noncoding O
part O
of O
the O
CPO O
gene O
, O
574 O
bp O
downstream O
of O
the O
last O
base O
of O
the O
normal O
termination O
codon O
( O
+ O
574 O
delATTCTT O
) O
. O

Five O
intragenic O
dimorphisms O
are O
now O
well O
characterized O
and O
the O
high O
degree O
of O
allelic O
heterogeneity O
in O
HC B
is O
demonstrated O
with O
seven O
new O
different O
mutations O
making O
a O
total O
of O
nineteen O
CPO O
gene B
defects I
reported O
so O
far O
. O
. O

Coincidence O
of O
two O
novel O
arylsulfatase O
A O
alleles O
and O
mutation O
459 O
+ O
1G O
> O
A O
within O
a O
family O
with O
metachromatic B
leukodystrophy I
: O
molecular O
basis O
of O
phenotypic O
heterogeneity O
. O

In O
a O
family O
with O
three O
siblings O
, O
one O
developed O
classical O
late O
infantile O
metachromatic B
leukodystrophy I
( O
MLD B
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
deficient O
arylsulfatase O
A O
( O
ARSA O
) O
activity O
and O
increased O
galactosylsulfatide O
( O
GS O
) O
excretion O
. O

The O
two O
other O
siblings O
, O
apparently O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
respectively O
, O
and O
their O
father O
, O
apparently O
healthy O
as O
well O
, O
presented O
ARSA O
and O
GS O
values O
within O
the O
range O
of O
MLD B
patients O
. O

Mutation O
screening O
and O
sequence O
analysis O
disclosed O
the O
involvement O
of O
three O
different O
ARSA O
mutations O
being O
the O
molecular O
basis O
of O
intrafamilial O
phenotypic O
heterogeneity O
. O

The O
late O
infantile O
patient O
inherited O
from O
his O
mother O
the O
frequent O
0 O
- O
type O
mutation O
459 O
+ O
1G O
> O
A O
, O
and O
from O
his O
father O
a O
novel O
, O
single O
basepair O
microdeletion O
of O
guanine O
at O
nucleotide O
7 O
in O
exon O
1 O
( O
7delG O
) O
. O

The O
two O
clinically O
unaffected O
siblings O
carried O
the O
maternal O
mutation O
459 O
+ O
1G O
> O
A O
and O
, O
on O
their O
paternal O
allele O
, O
a O
novel O
cytosine O
to O
thymidine O
transition O
at O
nucleotide O
2435 O
in O
exon O
8 O
, O
resulting O
in O
substitution O
of O
alanine O
464 O
by O
valine O
( O
A464V O
) O
. O

The O
fathers O
genotype O
thus O
was O
7delG O
/ O
A464V O
. O

Mutation O
A464V O
was O
not O
found O
in O
18 O
unrelated O
MLD B
patients O
and O
50 O
controls O
. O

A464V O
, O
although O
clearly O
modifying O
ARSA O
and O
GS O
levels O
, O
apparently O
bears O
little O
significance O
for O
clinical O
manifestation O
of O
MLD B
, O
mimicking O
the O
frequent O
ARSA O
pseudodeficiency O
allele O
. O

Our O
results O
demonstrate O
that O
in O
certain O
genetic O
conditions O
MLD B
- O
like O
ARSA O
and O
GS O
values O
need O
not O
be O
paralleled O
by O
clinical O
disease O
, O
a O
finding O
with O
serious O
diagnostic O
and O
prognostic O
implications O
. O

Moreover O
, O
further O
ARSA O
alleles O
functionally O
similar O
to O
A464V O
might O
exist O
which O
, O
together O
with O
0 O
- O
type O
mutations O
, O
may O
cause O
pathological O
ARSA O
and O
GS O
levels O
, O
but O
not O
clinical O
outbreak O
of O
the O
disease O
. O
. O

Human O
MLH1 O
deficiency O
predisposes O
to O
hematological B
malignancy I
and O
neurofibromatosis B
type I
1 I
. O

Heterozygous O
germ O
- O
line O
mutations O
in O
the O
DNA O
mismatch O
repair O
genes O
lead O
to O
hereditary B
nonpolyposis I
colorectal I
cancer I
. O

The O
disease O
susceptibility O
of O
individuals O
who O
constitutionally O
lack O
both O
wild O
- O
type O
alleles O
is O
unknown O
. O

We O
have O
identified O
three O
offspring O
in O
a O
hereditary B
nonpolyposis I
colorectal I
cancer I
family O
who O
developed O
hematological B
malignancy I
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B
type I
1 I
( O
NF1 B
) O
. O

DNA O
sequence O
analysis O
and O
allele O
- O
specific O
amplification O
in O
two O
siblings O
revealed O
a O
homozygous O
MLH1 O
mutation O
( O
C676T O
- O
- O
> O
Arg226Stop O
) O
. O

Thus O
, O
a O
homozygous O
germ O
- O
line O
MLH1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B
and O
/ O
or O
lymphoma B
associated O
with O
neurofibromatosis B
type I
1 I
. O
. O

Missense O
mutations O
in O
the O
most O
ancient O
residues O
of O
the O
PAX6 O
paired O
domain O
underlie O
a O
spectrum O
of O
human O
congenital B
eye I
malformations I
. O

Mutations O
of O
the O
human O
PAX6 O
gene O
underlie O
aniridia B
( O
congenital B
absence I
of I
the I
iris I
) O
, O
a O
rare O
dominant O
malformation B
of I
the I
eye I
. O

The O
spectrum O
of O
PAX6 O
mutations O
in O
aniridia B
patients O
is O
highly O
biased O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
leading O
to O
premature O
truncation O
of O
the O
protein O
( O
nonsense O
, O
splicing O
, O
insertions O
and O
deletions O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
another O
( O
missense O
) O
. O

The O
extraordinary O
conservation O
of O
the O
PAX6 O
protein O
at O
the O
amino O
acid O
level O
amongst O
vertebrates O
predicts O
that O
pathological O
missense O
mutations O
should O
in O
fact O
be O
common O
even O
though O
they O
are O
hardly O
ever O
seen O
in O
aniridia B
patients O
. O

This O
indicates O
that O
there O
is O
a O
heavy O
ascertainment O
bias O
in O
the O
selection O
of O
patients O
for O
PAX6 O
mutation O
analysis O
and O
that O
the O
missing O
PAX6 O
missense O
mutations O
frequently O
may O
underlie O
phenotypes O
distinct O
from O
textbook O
aniridia B
. O

Here O
we O
present O
four O
novel O
PAX6 O
missense O
mutations O
, O
two O
in O
association O
with O
atypical O
phenotypes O
ectopia B
pupillae I
( O
displaced B
pupils I
) O
and O
congenital B
nystagmus I
( O
searching B
gaze I
) O
, O
and O
two O
in O
association O
with O
more O
recognizable O
aniridia B
phenotypes O
. O

Strikingly O
, O
all O
four O
mutations O
are O
located O
within O
the O
PAX6 O
paired O
domain O
and O
affect O
amino O
acids O
which O
are O
highly O
conserved O
in O
all O
known O
paired O
domain O
proteins O
. O

Our O
results O
support O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
missense O
mutations O
is O
caused O
by O
ascertainment O
bias O
and O
suggest O
that O
a O
substantial O
burden O
of O
PAX6 B
- I
related I
disease I
remains O
to O
be O
uncovered O
. O
. O

The O
chromosomal O
order O
of O
genes O
controlling O
the O
major O
histocompatibility O
complex O
, O
properdin O
factor O
B O
, O
and O
deficiency B
of I
the I
second I
component I
of I
complement I
. O

The O
relationship O
of O
the O
genes O
coding O
for O
HLA O
to O
those O
coding O
for O
properdin O
Factor O
B O
allotypes O
and O
for O
deficiency B
of I
the I
second I
component I
of I
complement I
( O
C2 O
) O
was O
studied O
in O
families O
of O
patients O
with O
connective O
tissue O
disorders O
. O

Patients O
were O
selected O
because O
they O
were O
heterozygous O
or O
homozygous O
for O
C2 B
deficiency I
. O

12 O
families O
with O
15 O
matings O
informative O
for O
C2 B
deficiency I
were O
found O
. O

Of O
57 O
informative O
meioses O
, O
two O
crossovers O
were O
noted O
between O
the O
C2 B
deficiency I
gene O
and O
the O
HLA O
- O
B O
gene O
, O
with O
a O
recombinant O
fraction O
of O
0 O
. O

035 O
. O

A O
lod O
score O
of O
13 O
was O
calculated O
for O
linkage O
between O
C2 B
deficiency I
and O
HLA O
- O
B O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

04 O
. O

18 O
families O
with O
21 O
informative O
matings O
for O
both O
properdin O
Factor O
B O
allotype O
and O
HLA O
- O
B O
were O
found O
. O

Of O
72 O
informative O
meioses O
, O
three O
recombinants O
were O
found O
, O
giving O
a O
recombinant O
fraction O
of O
0 O
. O

042 O
. O

A O
lod O
score O
of O
16 O
between O
HLA O
- O
B O
and O
Factor O
B O
allotypes O
was O
calculated O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

04 O
. O

A O
crossover O
was O
shown O
to O
have O
occurred O
between O
genes O
for O
Factor O
B O
and O
HLA O
- O
D O
, O
in O
which O
HLA O
- O
D O
segregared O
with O
HLA O
- O
A O
and O
B O
. O

These O
studies O
suggest O
that O
the O
genes O
for O
Factor O
B O
and O
C2 B
deficiency I
are O
located O
outside O
those O
for O
HLA O
, O
that O
the O
order O
of O
genese O
is O
HLA O
- O
A O
, O
- O
B O
, O
- O
D O
, O
Factor O
B O
allotype O
, O
C2 B
deficiency I
, O
that O
the O
genes O
coding O
for O
C2 B
deficiency I
and O
Factor O
B O
allotypes O
are O
approximately O
3 O
- O
- O
5 O
centimorgans O
from O
the O
HLA O
- O
A O
and O
HLA O
- O
B O
loci O
, O
and O
that O
the O
apparent O
lack O
of O
recombinants O
between O
the O
Factor O
B O
gene O
and O
C2 B
deficiency I
gene O
suggests O
that O
these O
two O
genes O
lie O
in O
close O
proximity O
to O
one O
another O
. O

Distribution O
of O
emerin O
and O
lamins O
in O
the O
heart O
and O
implications O
for O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
. O

Emerin O
is O
a O
nuclear O
membrane O
protein O
which O
is O
missing O
or O
defective O
in O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EDMD B
) O
. O

It O
is O
one O
member O
of O
a O
family O
of O
lamina O
- O
associated O
proteins O
which O
includes O
LAP1 O
, O
LAP2 O
and O
lamin O
B O
receptor O
( O
LBR O
) O
. O

A O
panel O
of O
16 O
monoclonal O
antibodies O
( O
mAbs O
) O
has O
been O
mapped O
to O
six O
specific O
sites O
throughout O
the O
emerin O
molecule O
using O
phage O
- O
displayed O
peptide O
libraries O
and O
has O
been O
used O
to O
localize O
emerin O
in O
human O
and O
rabbit O
heart O
. O

Several O
mAbs O
against O
different O
emerin O
epitopes O
did O
not O
recognize O
intercalated O
discs O
in O
the O
heart O
, O
though O
they O
recognized O
cardiomyocyte O
nuclei O
strongly O
, O
both O
at O
the O
rim O
and O
in O
intranuclear O
spots O
or O
channels O
. O

A O
polyclonal O
rabbit O
antiserum O
against O
emerin O
did O
recognize O
both O
nuclear O
membrane O
and O
intercalated O
discs O
but O
, O
after O
affinity O
purification O
against O
a O
pure O
- O
emerin O
band O
on O
a O
western O
blot O
, O
it O
stained O
only O
the O
nuclear O
membrane O
. O

These O
results O
would O
not O
be O
expected O
if O
immunostaining O
at O
intercalated O
discs O
were O
due O
to O
a O
product O
of O
the O
emerin O
gene O
and O
, O
therefore O
, O
cast O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B
defects I
in O
EDMD B
are O
caused O
by O
absence O
of O
emerin O
from O
intercalated O
discs O
. O

Although O
emerin O
was O
abundant O
in O
the O
membranes O
of O
cardiomyocyte O
nuclei O
, O
it O
was O
absent O
from O
many O
non O
- O
myocyte O
cells O
in O
the O
heart O
. O

This O
distribution O
of O
emerin O
was O
similar O
to O
that O
of O
lamin O
A O
, O
a O
candidate O
gene O
for O
an O
autosomal O
form O
of O
EDMD B
. O

In O
contrast O
, O
lamin O
B1 O
was O
absent O
from O
cardiomyocyte O
nuclei O
, O
showing O
that O
lamin O
B1 O
is O
not O
essential O
for O
localization O
of O
emerin O
to O
the O
nuclear O
lamina O
. O

Lamin O
B1 O
is O
also O
almost O
completely O
absent O
from O
skeletal O
muscle O
nuclei O
. O

In O
EDMD B
, O
the O
additional O
absence O
of O
lamin O
B1 O
from O
heart O
and O
skeletal O
muscle O
nuclei O
which O
already O
lack O
emerin O
may O
offer O
an O
alternative O
explanation O
of O
why O
these O
tissues O
are O
particularly O
affected O
. O
. O

Genetic O
mapping O
of O
the O
copper B
toxicosis I
locus O
in O
Bedlington O
terriers O
to O
dog O
chromosome O
10 O
, O
in O
a O
region O
syntenic O
to O
human O
chromosome O
region O
2p13 O
- O
p16 O
. O

Abnormal O
hepatic B
copper I
accumulation I
is O
recognized O
as O
an O
inherited B
disorder I
in O
man O
, O
mouse O
, O
rat O
and O
dog O
. O

The O
major O
cause O
of O
hepatic B
copper I
accumulation I
in O
man O
is O
a O
dysfunctional O
ATP7B O
gene O
, O
causing O
Wilson B
disease I
( O
WD B
) O
. O

Mutations O
in O
the O
ATP7B O
genes O
have O
also O
been O
demonstrated O
in O
mouse O
and O
rat O
. O

The O
ATP7B O
gene O
has O
been O
excluded O
in O
the O
much O
rarer O
human O
copper B
overload I
disease O
non B
- I
Indian I
childhood I
cirrhosis I
, O
indicating O
genetic O
heterogeneity O
. O

By O
investigating O
the O
common O
autosomal O
recessive O
copper B
toxicosis I
( O
CT B
) O
in O
Bedlington O
terriers O
, O
we O
have O
identified O
a O
new O
locus O
involved O
in O
progressive O
liver B
disease I
. O

We O
examined O
whether O
the O
WD B
gene O
ATP7B O
was O
also O
causative O
for O
CT B
by O
investigating O
the O
chromosomal O
co O
- O
localization O
of O
ATP7B O
and O
C04107 O
, O
using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
. O

C04107 O
is O
an O
anonymous O
microsatellite O
marker O
closely O
linked O
to O
CT B
. O

However O
, O
BAC O
clones O
containing O
ATP7B O
and O
C04107 O
mapped O
to O
the O
canine O
chromosome O
regions O
CFA22q11 O
and O
CFA10q26 O
, O
respectively O
, O
demonstrating O
that O
WD B
cannot O
be O
homologous O
to O
CT B
. O

The O
copper O
transport O
genes O
CTR1 O
and O
CTR2 O
were O
also O
excluded O
as O
candidate O
genes O
for O
CT B
since O
they O
both O
mapped O
to O
canine O
chromosome O
region O
CFA11q22 O
. O

2 O
- O
22 O
. O

5 O
. O

A O
transcribed O
sequence O
identified O
from O
the O
C04107 O
- O
containing O
BAC O
was O
found O
to O
be O
homologous O
to O
a O
gene O
expressed O
from O
human O
chromosome O
2p13 O
- O
p16 O
, O
a O
region O
devoid O
of O
any O
positional O
candidate O
genes O
. O

Molecular O
analysis O
of O
the O
APC B
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
FAP B
and O
evidence O
for O
the O
role O
of O
APC B
amino O
acid O
changes O
in O
colorectal B
cancer I
predisposition O
. O

BACKGROUND O
/ O
AIMS O
The O
development O
of O
colorectal B
cancer I
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
mutations O
. O

In O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
APC B
gene O
was O
performed O
to O
determine O
genotype O
- O
phenotype O
correlations O
for O
nine O
extracolonic O
manifestations O
and O
to O
investigate O
the O
incidence O
of O
APC B
mutations O
in O
non O
- O
FAP O
colorectal B
cancer I
. O

METHODS O
The O
APC B
gene O
was O
analysed O
in O
190 O
unrelated O
FAP B
and O
15 O
non O
- O
FAP O
colorectal B
cancer I
patients O
using O
denaturing O
gradient O
gel O
electrophoresis O
, O
the O
protein O
truncation O
test O
, O
and O
direct O
sequencing O
. O

RESULTS O
Chain O
terminating O
signals O
were O
only O
identified O
in O
patients O
belonging O
to O
the O
FAP B
group O
( O
105 O
patients O
) O
. O

Amino O
acid O
changes O
were O
identified O
in O
four O
patients O
, O
three O
of O
whom O
belonged O
to O
the O
non O
- O
FAP O
group O
of O
colorectal B
cancer I
patients O
. O

Genotype O
- O
phenotype O
correlations O
identified O
significant O
differences O
in O
the O
nature O
of O
certain O
extracolonic O
manifestations O
in O
FAP B
patients O
belonging O
to O
three O
mutation O
subgroups O
. O

CONCLUSIONS O
Extended O
genotype O
- O
phenotype O
correlations O
made O
in O
this O
study O
may O
have O
the O
potential O
to O
determine O
the O
most O
appropriate O
surveillance O
and O
prophylactic O
treatment O
regimens O
for O
those O
patients O
with O
mutations O
associated O
with O
life O
threatening O
conditions O
. O

This O
study O
also O
provided O
evidence O
for O
the O
pathological O
nature O
of O
amino O
acid O
changes O
in O
APC O
associated O
with O
both O
FAP B
and O
non O
- O
FAP O
colorectal B
cancer I
patients O
. O
. O

Inherited B
colorectal I
polyposis I
and O
cancer B
risk O
of O
the O
APC O
I1307K O
polymorphism O
. O

Germ O
- O
line O
and O
somatic O
truncating O
mutations O
of O
the O
APC B
gene O
are O
thought O
to O
initiate O
colorectal B
tumor I
formation O
in O
familial B
adenomatous I
polyposis I
syndrome I
and O
sporadic O
colorectal O
carcinogenesis O
, O
respectively O
. O

Recently O
, O
an O
isoleucine O
- O
- O
> O
lysine O
polymorphism O
at O
codon O
1307 O
( O
I1307K O
) O
of O
the O
APC B
gene O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
Ashkenazi O
Jewish O
population O
. O

To O
assess O
the O
risk O
of O
this O
common O
APC B
allelic O
variant O
in O
colorectal O
carcinogenesis O
, O
we O
have O
analyzed O
a O
large O
cohort O
of O
unselected O
Ashkenazi O
Jewish O
subjects O
with O
adenomatous B
polyps I
and O
. O
or O
colorectal B
cancer I
, I
for O
the O
APC O
I1307K O
polymorphism O
. O

The O
APC O
I1307K O
allele O
was O
identified O
in O
48 O
( O
10 O
. O
1 O
% O
) O
of O
476 O
patients O
. O

Compared O
with O
the O
frequency O
in O
two O
separate O
population O
control O
groups O
, O
the O
APC O
I1307K O
allele O
is O
associated O
with O
an O
estimated O
relative O
risk O
of O
1 O
. O

5 O
- O
1 O
. O

7 O
for O
colorectal B
neoplasia I
( O
both O
P O
= O
. O
01 O
) O
. O

Furthermore O
, O
compared O
with O
noncarriers O
, O
APC O
I1307K O
carriers O
had O
increased O
numbers O
of O
adenomas B
and O
colorectal B
cancers I
per O
patient O
( O
P O
= O
. O
03 O
) O
, O
as O
well O
as O
a O
younger O
age O
at O
diagnosis O
. O

We O
conclude O
that O
the O
APC O
I1307K O
variant O
leads O
to O
increased O
adenoma B
formation O
and O
directly O
contributes O
to O
3 O
% O
- O
4 O
% O
of O
all O
Ashkenazi O
Jewish O
colorectal B
cancer I
. O

The O
estimated O
relative O
risk O
for O
carriers O
may O
justify O
specific O
clinical O
screening O
for O
the O
360 O
, O
000 O
Americans O
expected O
to O
harbor O
this O
allele O
, O
and O
genetic O
testing O
in O
the O
setting O
of O
long O
- O
term O
- O
outcome O
studies O
may O
impact O
significantly O
on O
colorectal B
cancer I
prevention O
in O
this O
population O
. O

Localization O
of O
human O
BRCA1 O
and O
its O
loss O
in O
high O
- O
grade O
, O
non B
- I
inherited I
breast I
carcinomas I
. O

Although O
the O
link O
between O
the O
BRCA1 O
tumour B
- O
suppressor O
gene O
and O
hereditary B
breast I
and I
ovarian I
cancer I
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
BRCA1 O
in O
non B
- I
familial I
cancers I
is O
unclear O
. O

BRCA1 O
mutations O
are O
rare O
in O
sporadic B
cancers I
, O
but O
loss O
of O
BRCA1 O
resulting O
from O
reduced O
expression O
or O
incorrect O
subcellular O
localization O
is O
postulated O
to O
be O
important O
in O
non B
- I
familial I
breast I
and I
ovarian I
cancers I
. O

Epigenetic O
loss O
, O
however O
, O
has O
not O
received O
general O
acceptance O
due O
to O
controversy O
regarding O
the O
subcellular O
localization O
of O
BRCA1 O
proteins O
, O
reports O
of O
which O
have O
ranged O
from O
exclusively O
nuclear O
, O
to O
conditionally O
nuclear O
, O
to O
the O
ER O
/ O
golgi O
, O
to O
cytoplasmic O
invaginations O
into O
the O
nucleus O
. O

In O
an O
attempt O
to O
resolve O
this O
issue O
, O
we O
have O
comprehensively O
characterized O
19 O
anti O
- O
BRCA1 O
antibodies O
. O

These O
reagents O
detect O
a O
220 O
- O
kD O
protein O
localized O
in O
discrete O
nuclear O
foci O
in O
all O
epithelial O
cell O
lines O
, O
including O
those O
derived O
from O
breast B
malignancies I
. O

Immunohistochemical O
staining O
of O
human O
breast O
specimens O
also O
revealed O
BRCA1 O
nuclear O
foci O
in O
benign O
breast O
, O
invasive B
lobular I
cancers I
and O
low B
- I
grade I
ductal I
carcinomas I
. O

Conversely O
, O
BRCA1 O
expression O
was O
reduced O
or O
undetectable O
in O
the O
majority O
of O
high O
- O
grade O
, O
ductal B
carcinomas I
, O
suggesting O
that O
absence O
of O
BRCA1 O
may O
contribute O
to O
the O
pathogenesis O
of O
a O
significant O
percentage O
of O
sporadic B
breast I
cancers I
. O
. O

